In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory...
66 months ago

Dementia with Lewy bodies (DLB) is an age-associated neurodegenerative disorder producing progressive cognitive decline that interferes with normal life and...
70 months ago

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease, with a complex pathogenesis and an irreversible course.
5 months ago

The added value of emerging cerebrospinal fluid (CSF) markers (Aβ40, Aβ38, BACE-1, neurogranin [ng], phosphorylated neurofilament heavy...
48 months ago

Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed.
14 months ago

Reliable biomarkers are needed for early and accurate diagnosis, to measure disease progression, and response to therapy.
9 months ago

Studies within the last few decades provide growing evidence for a central role of amyloid β (Aβ) and tau, as well as glial contributions to various molecular...
52 months ago

In this review, we discuss AD biomarkers which can be reliably measured in CSF and plasma using targeted mass spectrometry coupled to liquid chromatography (LC...
40 months ago

We conclude that CSF LCN2 is a promising candidate biochemical marker in the differential diagnosis of VaD and neurodegenerative dementias.
58 months ago

Dementia is an umbrella term—caused by a large number of specific diagnoses, including several neurodegenerative disorders. Alzheimer's disease (AD) is now...
9 months ago